Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

Date publication

janvier 2021

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FACY Olivier , Pr MARCHAL Frédéric

Tous les auteurs :
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33476595

Résumé

The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic resection. We aimed to assess the specific benefit of adding HIPEC to cytoreductive surgery compared with receiving cytoreductive surgery alone.

Référence

Lancet Oncol. 2021 Jan 18;: